Other News To Note
Celgene International Sàrl, of Boudry, Switzerland, submitted a marketing authorization application for the approval of Revlimid (lenalidomide) as a maintenance treatment for newly diagnosed multiple myeloma patients who have not progressed following initial treatment with melphalan, prednisone and Revlimid, or following autologous stem cell transplantation.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter